US rejects Sharif's call to get involved on Kashmir

October 21, 2013
kerry
Washington, Oct 21: Even before Pakistan Prime Minister Nawaz Sharif landed here for a four-day visit, the US rejected out of hand his call for Washington to get involved to resolve the Kashmir issue.

"On Kashmir, our policy has not changed an iota," a senior administration official said in a background conference call Sunday reiterating US' oft-stated stand that Kashmir issue was a bilateral one between the two South Asian neighbours.

While it encouraged a dialogue between the two countries "the pace, scope, and character of India and Pakistan's dialogue on Kashmir is for those two countries to determine with each other," the official said.

The official was responding to comments made earlier Sunday by Sharif in London on way to Washington that even though India does not want it, world powers should get involved to resolve the Kashmir issue.

The world powers should do so as India and Pakistan both were nuclear powers and the region was a nuclear flash point, he was quoted as saying by the Associated Press of Pakistan.

But the US official did expect "India to come up at some point" during Sharif's first meeting Wednesday with US President Barack Obama nearly a month after Indian Prime Minister's Sep 27 summit with Obama at the White House.

While the focus of the Obama-Sharif meeting would be bilateral relationship, including energy, economy and extremism, in addition to Afghanistan, the official said, "We expect India to come up at some point."

"We have been very encouraged by steps that both India and Pakistan have taken," he said "to resolve issues on the trade and energy side, in keeping with the "energy and economy theme" that Obama and Sharif would explore here.

"Obviously (they are) very positive," he said referring to the steps taken since Sharif's meeting with Manmohan Singh on the sidelines of the UN general assembly in New York just two days after a summit with Obama where he had called Pakistan as the epicentre of terrorism.

Like India, US officials too expressed concern that terrorism emanating from inside Pakistan could derail on-going peace talks between India and Pakistan after Sharif was voted to power in May this year.

"Cleary we would be concerned about the terrorist groups that would derail that dialogue process," the official said.

Meanwhile, meeting Sharif over dinner Sunday night, Secretary of State John Kerry said "We're very anxious to have a series of high-level, important discussions over the course of the next few days - the Vice President (Joe Biden), the President, tonight's dinner."

"We have a lot to talk about and the relationship with Pakistan could not be more important. On its own, a democracy that is working hard to get its economy moving and deal with insurgency and also important to the regional stability," he said.

Sharif, who last visited Washington in 1999 during the Kargil war before he was overthrown in a coup by Gen Pervez Musharraf, will hold a series of meetings with the top US officials and lawmakers on Capitol Hill.

Earlier
Nawaz Sharif meets US Secretary of State John Kerry

Washington, Oct 21: Visiting Pakistan Prime Minister Nawaz Sharif on Monday met U.S. Secretary of State John Kerry and discussed a wide range of bilateral and regional issues, the State Department said.

“Secretary Kerry's meeting with the PM (Sharif) is their third in three months, and continued the robust dialogue on our shared goal of a stable, secure and prosperous Pakistan,” a statement issued by the State Department said.

Sharif is in Washington on a four-day official visit to the U.S., and is scheduled to meet President Barack Obama on October 23.

He is accompanied by a high-powered delegation that includes Finance Minister Ishaq Dar, Adviser to the Prime Minister on National Security and Foreign Affairs Sartaj Aziz and Foreign Secretary Jalil Abbas Jilani.

Monday's discussions covered a broad range of domestic and regional issues including peace and security, counter-terrorism cooperation, collaboration on Pakistan's energy sector, increasing bilateral trade and investment and the common interest of a secure, stable Afghanistan, it said.

“Both sides agreed on the importance of our continued counterterrorism cooperation, and that extremism is countered in part by opportunities arising from greater economic stability.

“To that end, the U.S., Pakistan's largest trading partner, remains committed to an economic relationship increasingly based on trade and investment,” the statement said.

Meanwhile, the Obama administration has requested the U.S. Congress to resume the security assistance to Pakistan, which now stands at 305 million U.S. dollars for fiscal year 2014, a drop of 35 per cent as compared to the 2012 fiscal.

The drop is because the Administration has not asked for a renewal of temporary Pakistan Counterinsurgency Capability Fund (PCCF), which was started in the year 2009, a senior administration official told PTI.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 4,2020

Geneva, Jul 4: The World Health Organization has updated its account of the early stages of the COVID crisis to say it was alerted by its own office in China, and not by China itself, to the first pneumonia cases in Wuhan.

The UN health body has been accused by US President Donald Trump of failing to provide the information needed to stem the pandemic and of being complacent towards Beijing, charges it denies.

On April 9, WHO published an initial timeline of its communications, partly in response to criticism of its early response to the outbreak that has now claimed more than 521,000 lives worldwide.

In that chronology, WHO had said only that the Wuhan municipal health commission in the province of Hubei had on December 31 reported cases of pneumonia. The UN health agency did not however specify who had notified it.

WHO director Tedros Adhanom Ghebreyesus told a press conference on April 20 the first report had come from China, without specifying whether the report had been sent by Chinese authorities or another source.

But a new chronology, published this week by the Geneva-based institution, offers a more detailed version of events.

It indicates that it was the WHO office in China that on December 31 notified its regional point of contact of a case of "viral pneumonia" after having found a declaration for the media on a Wuhan health commission website on the issue.

The same day, WHO's epidemic information service picked up another news report transmitted by the international epidemiological surveillance network ProMed -- based in the United States -- about the same group of cases of pneumonia from unknown causes in Wuhan.

After which, WHO asked the Chinese authorities on two occasions, on January 1 and January 2, for information about these cases, which they provided on January 3.

WHO emergencies director Michael Ryan told a press conference on Friday that countries have 24-48 hours to officially verify an event and provide the agency with additional information about the nature or cause of an event.

Ryan added that the Chinese authorities immediately contacted WHO's as soon as the agency asked to verify the report.

US President Donald Trump has announced that his country, the main financial contributor to WHO, will cut its bridges with the institution, which he accuses of being too close to China and of having poorly managed the pandemic.

The WHO denies any complacency toward China.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
February 12,2020

London, Feb 12: Fugitive liquor baron Vijay Mallya returned to the courtroom here on Wednesday, the second day of hearing at the UK High Court, where the former billionaire has appealed against the extradition decision of Westminster Magistrates Court in December 2018.

On being asked about his expectations from the lengthy appeals process against the extradition order as today is the last day for Mallya to present his defence, the embattled former Kingfisher Airlines boss replied, "I have no clue. You see. I'll also see it. Let's not get into a speculative game."

When asked on what would happen if Mallya loses the case and has to return to India, the liquor baron responded: "We do have arguments."

The UK High Court, on Tuesday, had also heard Mallya's appeal against the Westminster Magistrates' Court order extraditing him to India to face alleged fraud and money laundering charges amounting to Rs 9,000 crore.

Mallya was present in the court along with his counsel Clare Montgomery during the hearing. Officials from Enforcement Directorate (ED) and Central Bureau of Investigation (CBI) along with counsel Mark Summers representing the Indian government were also present.

When the judge asked if there was a timeline in the case, Clare said," This is a very dense case," involving multiple individuals and organisations and that not everything had been taken into account by the magistrate Emma Arbuthnot in her ruling against Mallya.

Montgomery contended that the magistrate's ruling had been riddled with "multiple errors". She also brought into question the admissibility of documents submitted by the Indian government - including witness statements and emails that proved crucial in the ruling by judge Arbuthnot, who found "clear evidence of misapplication of loan funds" and that there was a prima facie case of fraud against Mallya.

As she had done throughout the trial, Montgomery continued to assert that Mallya had not acted in a fraudulent manner or run a pyramid and that the collapse of Kingfisher Airlines was, in fact, the failure of a business in difficult economic circumstances.

She also reiterated concerns about the conduct of the Central Bureau of Investigation (CBI) in bringing charges against Mallya, claiming that the tycoon had been made a scapegoat.

Montgomery also stated that the Indian government had presented the loan taken out by Kingfisher Airlines, not as a simple business loan but was part of a larger and elaborate attempt at defrauding the banks by Mallya and Kingfisher Airlines management.

This, Montgomery contended, was but one example of a wider misinterpretation of the case by judge Arbuthnot.

The High Court justices reprimanded Montgomery for concentrating on the evidence - in essence rehashing the case presented at the lower court - rather than the apparent "mistakes" made by judge Arbuthnot in her ruling.

Mallya remains on bail of £650,000 as he has done throughout this legal process.

The Crown Prosecution Service which is representing the Government of India will present its case for the extradition of Mallya on Wednesday.

The 63-year-old businessman fled India in March 2016 and has been living in the UK since then.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.